Artax Biopharma
PrivateLast Round
Convertible Debt
Aug 6, 2024
Est. Valuation
$51.35M
Total Funding Raised
$44M
Company Overview
Artax Biopharma operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Convertible Debt round in August 2024.
Artax Biopharma is a biotechnology company that develops small molecule drugs designed to treat autoimmune and inflammatory diseases by targeting T cell-mediated immune responses.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Artax Biopharma Comparables
Compare Artax Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LAPIX Therapeutics | 85% | |
| Forward Therapeutics | 80% | |
| SFA Therapeutics | 80% |
For institutional investors. Book with your work email.
Artax Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Aug 6, 2024 | ||||
| Early Stage VC | Jul 31, 2024 | ||||
| Series C | May 11, 2022 | ||||
| Series B Extension | Jun 4, 2020 | ||||
| Early Funding | Jul 31, 2019 | ||||
Series B | Sep 22, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Artax Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Columbus Ventures | Convertible Debt |
| A. M. Pappas & Associates | Series B |
| Advent Life Sciences | Convertible Debt, Series C, Series B |
| Columbus Venture Partners | Convertible Debt, Series C, Series B Extension |
| Sound Bioventures | Convertible Debt, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 7, 2025
Presented preclinical data at the 2025 American Academy of Dermatology Annual Meeting.
- Mar 7, 2025
New preclinical data for Nck modulators presented at AAD Annual Meeting.
For institutional investors. Book with your work email.
Artax Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Artax Biopharma's valuation, stock price, and market status.
Is Artax Biopharma a public or private company?
Artax Biopharma is a private company.
What is the current stock price of Artax Biopharma?
Artax Biopharma is a private company, so its shares have no public market price. Caplight tracks Artax Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Artax Biopharma worth (valuation)?
Artax Biopharma's valuation is estimated at $51.4M based on funding round data.
Can I buy Artax Biopharma stock?
Artax Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Artax Biopharma's last funding round?
Artax Biopharma's most recent funding round was Convertible Debt on August 6, 2024.
Who are the main investors in Artax Biopharma?
Key investors in Artax Biopharma include Advent Life Sciences, Columbus Venture Partners, Sound Bioventures.
Will Artax Biopharma IPO soon?
No public IPO plans have been announced for Artax Biopharma.
How can I track Artax Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Artax Biopharma's shares on secondary markets.